Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs SK 1403 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Sanwa Kagaku Kenkyusho
- 09 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.